Lonza raises Sfr2.25bn in successful Capsugel rights issue
Lonza, the Swiss pharmaceuticals group, has completed its Sfr2.25bn rights issue, to part-finance its takeover of Capsugel, the US maker of medicine capsules, from KKR.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: